Journal
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
Volume 19, Issue 5, Pages 482-487Publisher
SAGE PUBLICATIONS INC
DOI: 10.1177/1076029613492876
Keywords
apixaban; heparin; anticoagulant; platelets; heparin-induced thrombocytopenia
Categories
Funding
- Bristol-Myers Squibb
- Pfizer Inc.
Ask authors/readers for more resources
Due to the pronounced hypercoagulable state in heparin-induced thrombocytopenia (HIT), alternatives to heparin that do not interact with HIT antibodies are needed for anticoagulation management. This study was designed to determine whether the oral factor Xa inhibitor apixaban could be used. Functional platelet activation with apixaban in the presence of HIT antibodies was evaluated by the C-14-serotonin release assay (SRA; washed platelets) and the heparin-induced platelet aggregation assay (PA-HIT; platelet-rich plasma). A consistent absence of platelet activation by apixaban (0.05-50 mu g/mL) was observed: SRA (n = 35) 11 +/- 4% and PA-HIT (n = 37) 8 +/- 3% (mean +/- standard error of the mean; positive is > 20%) versus heparin (0.1 U/mL) 82 +/- 3% SRA and 78 +/- 6% PA-HIT (P < 0.01) versus enoxaparin (10 mu g/mL) 73 +/- 5% SRA and 62 +/- 7% PA-HIT. Apixaban may provide an option for oral anticoagulation in patients with HIT, particularly for extended management and prevention.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available